| Assay ID | Title | Year | Journal | Article |
|---|
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID445960 | Agonist activity at human recombinant cannabinoid CB2 receptor expressed in MMY23 Saccharomyces cerevisiae assessed as degradation of FDGlu to fluorescein after 24 hrs by spectrofluorimetry relative to HU210 | 2009 | Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
| Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain. |
| AID288439 | Drug concentration in blood of rat FCA model of inflammatory pain at 0.3 mg/kg, po after 1hr | 2007 | Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
| Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. |
| AID288434 | Half life in rat | 2007 | Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
| Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. |
| AID445969 | Solubility in simulated intestinal fluid at pH 5 | 2009 | Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
| Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain. |
| AID1491459 | Agonist activity at CB2 receptor (unknown origin) expressed in CHO cells assessed as induction of calcium mobilization by fluo-4 AM dye-based fluorescence assay relative to CP55940 | 2017 | European journal of medicinal chemistry, Sep-08, Volume: 137 | Developing pyridazine-3-carboxamides to be CB2 agonists: The design, synthesis, structure-activity relationships and docking studies. |
| AID288441 | Reversal of FCA-induced hyperalgesia in rat administered thrice daily at 1 mg/kg, po | 2007 | Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
| Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. |
| AID412566 | Displacement of [3H]CP-55940 from human recombinant CB2 receptor | 2009 | Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
| Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. |
| AID288433 | Oral bioavailability in rat | 2007 | Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
| Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. |
| AID1491455 | Agonist activity at CB2 receptor (unknown origin) expressed in CHO cells assessed as induction of calcium mobilization at 10 uM by fluo-4 AM dye-based fluorescence assay relative to CP55940 | 2017 | European journal of medicinal chemistry, Sep-08, Volume: 137 | Developing pyridazine-3-carboxamides to be CB2 agonists: The design, synthesis, structure-activity relationships and docking studies. |
| AID288426 | Inhibition of human CYP1A2 | 2007 | Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
| Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. |
| AID288431 | Agonist activity at rat CB2 receptor | 2007 | Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
| Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. |
| AID288435 | Analgesic activity in po dosed rat FCA model of inflammatory pain | 2007 | Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
| Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. |
| AID1454519 | Lipophilicity, log P of the compound incubated at 37 degC for 20 hrs by HPLC based shake flask method | | | |
| AID419011 | Agonist activity at human CB2 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP release | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Morpholine containing CB2 selective agonists. |
| AID288438 | Drug concentration in blood of rat FCA model of inflammatory pain at 0.1 mg/kg, po after 1hr | 2007 | Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
| Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. |
| AID288423 | Efficacy at human recombinant CB2 receptor expressed in Saccharomyces cerevisiae cells relative to HU210 | 2007 | Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
| Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. |
| AID1491453 | Agonist activity at CB1 receptor (unknown origin) expressed in CHO cells assessed as induction of calcium mobilization at 10 uM by fluo-4 AM dye-based fluorescence assay relative to CP55940 | 2017 | European journal of medicinal chemistry, Sep-08, Volume: 137 | Developing pyridazine-3-carboxamides to be CB2 agonists: The design, synthesis, structure-activity relationships and docking studies. |
| AID288422 | Agonist activity at human recombinant CB2 receptor expressed in Saccharomyces cerevisiae cells | 2007 | Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
| Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. |
| AID288429 | Inhibition of human CYP2D6 | 2007 | Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
| Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. |
| AID1454518 | Ratio of EC50 for agonist activity at CB1 receptor (unknown origin) expressed in CHO cells to EC50 for agonist activity at CB2 receptor (unknown origin) expressed in CHO cells | | | |
| AID412164 | Aqueous solubility at pH 7.4 | 2009 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
| Pyridine-3-carboxamides as novel CB(2) agonists for analgesia. |
| AID1234245 | Agonist activity at CB2R (unknown origin) CHO cells stably expressing Galpha16 assessed as increase in intracellular calcium level by microplate reader based assay relative to CP55940 | 2015 | Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
| Development of Quinoline-2,4(1H,3H)-diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor. |
| AID288436 | Reversal of hyperalgesia in rat at 0.3 mg/kg, po by weight bearing protocol | 2007 | Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
| Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. |
| AID1454516 | Agonist activity at CB2 receptor (unknown origin) expressed in CHO cells co-expressing G-alpha16 incubated for 24 hrs by fluo-4 AM dye based whole-cell calcium mobilization assay | | | |
| AID445959 | Agonist activity at human recombinant cannabinoid CB2 receptor expressed in MMY23 Saccharomyces cerevisiae assessed as degradation of FDGlu to fluorescein after 24 hrs by spectrofluorimetry | 2009 | Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
| Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain. |
| AID1198059 | Selectivity index, ratio of EC50 for CB1 receptor (unknown origin) to EC50 for CB2 receptor (unknown origin) | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor. |
| AID419013 | Selectivity ratio of EC50 for human CB1 receptor to EC50 for human CB2 receptor | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Morpholine containing CB2 selective agonists. |
| AID288427 | Inhibition of human CYP2C9 | 2007 | Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
| Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. |
| AID1491460 | Selectivity index, ratio of EC50 for CB1 receptor (unknown origin) to EC50 for CB2 receptor (unknown origin) | 2017 | European journal of medicinal chemistry, Sep-08, Volume: 137 | Developing pyridazine-3-carboxamides to be CB2 agonists: The design, synthesis, structure-activity relationships and docking studies. |
| AID314554 | Selectivity for human CB1 receptor over human CB2 receptor by cAMP assay | 2008 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
| Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity. |
| AID314552 | Agonist activity at human CB2 receptor expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP level | 2008 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
| Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity. |
| AID288437 | Drug concentration in blood of rat FCA model of inflammatory pain at 0.03 mg/kg, po after 1hr | 2007 | Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
| Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. |
| AID323712 | Agonist activity at CB1 receptor | 2008 | Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
| Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action. |
| AID445957 | Agonist activity at human recombinant cannabinoid CB1 receptor expressed in MMY23 Saccharomyces cerevisiae assessed as degradation of FDGlu to fluorescein after 24 hrs by spectrofluorimetry | 2009 | Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
| Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain. |
| AID1234246 | Selectivity index, ratio of EC50 for CB1R (unknown origin) CHO cells stably expressing Galpha16 to EC50 for CB2R (unknown origin) CHO cells stably expressing Galpha16 | 2015 | Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
| Development of Quinoline-2,4(1H,3H)-diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor. |
| AID419012 | Agonist activity at human CB2 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP release relative to CP-55940 | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Morpholine containing CB2 selective agonists. |
| AID1454517 | Agonist activity at CB2 receptor (unknown origin) expressed in CHO cells co-expressing G-alpha16 incubated for 24 hrs by fluo-4 AM dye based whole-cell calcium mobilization assay relative to CP55940 | | | |
| AID323713 | Agonist activity at CB2 receptor | 2008 | Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
| Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action. |
| AID1198057 | Agonist activity at CB2 receptor (unknown origin) expressed in CHO cells by calcium mobilization assay | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor. |
| AID419016 | Displacement of [3H]Win55212 form human CB2 receptor transfected in HEK cells | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Morpholine containing CB2 selective agonists. |
| AID1491458 | Agonist activity at CB2 receptor (unknown origin) expressed in CHO cells assessed as induction of calcium mobilization by fluo-4 AM dye-based fluorescence assay | 2017 | European journal of medicinal chemistry, Sep-08, Volume: 137 | Developing pyridazine-3-carboxamides to be CB2 agonists: The design, synthesis, structure-activity relationships and docking studies. |
| AID314553 | Agonist activity at human CB2 receptor expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP level relative to CP-55940 | 2008 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
| Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity. |
| AID1234243 | Agonist activity at CB1R (unknown origin) CHO cells stably expressing Galpha16 assessed as increase in intracellular calcium level by microplate reader based assay | 2015 | Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
| Development of Quinoline-2,4(1H,3H)-diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor. |
| AID1491457 | Agonist activity at CB1 receptor (unknown origin) expressed in CHO cells assessed as induction of calcium mobilization by fluo-4 AM dye-based fluorescence assay | 2017 | European journal of medicinal chemistry, Sep-08, Volume: 137 | Developing pyridazine-3-carboxamides to be CB2 agonists: The design, synthesis, structure-activity relationships and docking studies. |
| AID412565 | Displacement of [3H]CP-55940 from human recombinant CB1 receptor | 2009 | Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
| Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. |
| AID412567 | Selectivity ratio of Ki for human CB1 receptor to Ki for human CB2 receptor | 2009 | Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
| Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. |
| AID419015 | Displacement of [3H]CP-55940 form human CB2 receptor transfected in HEK cells | 2009 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
| Morpholine containing CB2 selective agonists. |
| AID288430 | Inhibition of human CYP3A4 | 2007 | Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
| Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. |
| AID288428 | Inhibition of human CYP2C19 | 2007 | Journal of medicinal chemistry, May-31, Volume: 50, Issue:11
| Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. |
| AID1198056 | Agonist activity at CB1 receptor (unknown origin) expressed in CHO cells by calcium mobilization assay | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor. |
| AID1234244 | Agonist activity at CB2R (unknown origin) CHO cells stably expressing Galpha16 assessed as increase in intracellular calcium level by microplate reader based assay | 2015 | Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
| Development of Quinoline-2,4(1H,3H)-diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor. |
| AID1491454 | Antagonist activity at CB1 receptor (unknown origin) expressed in CHO cells assessed as inhibition of CP55940-induced calcium mobilization at 10 uM preincubated for 10 mins followed by CP55940-induction by fluo-4 AM dye-based fluorescence assay relative t | 2017 | European journal of medicinal chemistry, Sep-08, Volume: 137 | Developing pyridazine-3-carboxamides to be CB2 agonists: The design, synthesis, structure-activity relationships and docking studies. |
| AID1454515 | Agonist activity at CB1 receptor (unknown origin) expressed in CHO cells co-expressing G-alpha16 incubated for 24 hrs by fluo-4 AM dye based whole-cell calcium mobilization assay | | | |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |